Purchase this article with an account.
I.M. Neuhann, F. Gelisken, F. Ziemssen, K. Karim–Zade, S. Grisanti, K.U. Bartz–Schmidt; Macular Translocation Surgery With 360 Degree Retinectomy Following Verteporfin Photodynamic Therapy of Choroidal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):215.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To determine the functional outcome in eyes that underwent macular translocation surgery with 360 degree retinectomy (MT–360) following verteporfin photodynamic therapy (verteporfin–PDT) of choroidal neovascularization secondary to age–related macular degeneration (AMD). Methods: Patients undergoing MT–360 between May 2002 and February 2004 at the Department of Ophthalmology of the University Hospital of Tuebingen were retrospectively located. Patients with at least one session of verteporfin–PDT and with a follow–up of at least six months were included in the study. Baseline best corrected visual acuity (BCVA), number and date of verteporfin–PDT and postoperative BCVA were recorded. Results: Six eyes from six patients were identified to fulfill the inclusion criteria. Preoperative BCVA ranged from 20/500 to 20/63. The mean number of verteporfin–PDT treatments before surgery was 2 (range 1–5). The mean time interval between the last verteporfin–PDT and the surgery was 2.7 months (range 1.3–4.4). In all cases the surgery was performed by one surgeon. The silicone oil was removed after a mean of 3.9 months (range 3.0–5.3). In all cases the extraocular muscle surgery for torsional diplopia was performed at the same time as the silicone oil removal. The postoperative BCVA after six months ranged from 20/1000 to 20/40. One patient gained one ETDRS line, four patients gained two or more ETDRS lines, and one patient lost three ETDRS lines. This patient had a history of two prior verteporfin–PDT treatments and the last episode lay back 1.3 months. In all six eyes no recurrence of CNV, no proliferative vitreoretinopathy associated with retinal detachment, no diplopia or tilted vision was recorded after a mean total follow–up of 16.9 months (range 8.0–25.6). Conclusions: The results obtained in our retrospective case series suggest that MT–360 is a therapeutical option for patients with neovascular AMD and visual deterioration who did not respond to verteporfin–PDT. Further studies with larger case numbers of patients should be undertaken to confirm this result.
This PDF is available to Subscribers Only